XNAS
BCTX
Market cap15mUSD
Sep 17, Last price
8.64USD
1D
5.24%
1Q
176.92%
Jan 2017
-80.80%
IPO
-92.58%
Name
Briacell Therapeutics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
95.26%
Rev. gr., 5y
%
Revenues
0k
Net income
-7k
L-99.97%
CFO
-24m
L+1.61%
Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | 2016‑07 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 160 | 23,272 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (160) | (23,272) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (153) | ||||||||
Tax Rate | |||||||||
NOPAT | (160) | (23,120) | |||||||
Net income | (7) -99.97% | (20,302) 75.31% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,419 | 3,953 | |||||||
BB yield | -391.09% | -2.93% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,096 | 29,139 | |||||||
Net debt | (1,281) | (21,251) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (24,126) | (23,745) | |||||||
CAPEX | (457) | ||||||||
Cash from investing activities | (682) | ||||||||
Cash from financing activities | 4,419 | 3,954 | |||||||
FCF | 7,136 | (26,633) | |||||||
| Balance | |||||||||
Cash | 862 | 21,251 | |||||||
Long term investments | 418 | 2 | |||||||
Excess cash | 1,281 | 21,251 | |||||||
Stockholders' equity | (13,718) | (11,199) | |||||||
Invested Capital | 12,130 | 36,561 | |||||||
ROIC | |||||||||
ROCE | 10.07% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 1,097 | 15,518 | |||||||
Price | 1.03 -88.13% | 8.68 4.45% | |||||||
Market cap | 1,130 -99.16% | 134,696 4.45% | |||||||
EV | (453) | 113,445 | |||||||
EBITDA | (76) | (23,257) | |||||||
EV/EBITDA | 5.95 | ||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||